Singlera Genomics and Breakthrough Genomics partnered with the University of Pittsburgh to run a preclinical study validating the BT‑Reveal Early Pancreatic Cancer Test, which analyzes cell‑free DNA methylation patterns using Singlera’s mTitan platform. The BT‑Reveal test holds FDA breakthrough device designation and is currently available as a laboratory‑developed test for high‑risk patients. The study will evaluate efficacy in high‑risk cohorts as a step toward a longitudinal FDA study. Singlera and Breakthrough framed the collaboration as a critical data‑generation step for potential large‑scale screening. If preclinical results support sensitivity and specificity in at‑risk populations, the program could progress to pivotal studies and influence the nascent market for blood‑based pancreatic cancer screening.